JPS58201994A - 抗原特異的ヒト免疫グロブリンの生産方法 - Google Patents

抗原特異的ヒト免疫グロブリンの生産方法

Info

Publication number
JPS58201994A
JPS58201994A JP57084843A JP8484382A JPS58201994A JP S58201994 A JPS58201994 A JP S58201994A JP 57084843 A JP57084843 A JP 57084843A JP 8484382 A JP8484382 A JP 8484382A JP S58201994 A JPS58201994 A JP S58201994A
Authority
JP
Japan
Prior art keywords
human
cell
cells
immunoglobulin
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57084843A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0159878B2 (https=
Inventor
Hideaki Hagiwara
秀昭 萩原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP57084843A priority Critical patent/JPS58201994A/ja
Priority to CA000428517A priority patent/CA1247538A/en
Priority to SK3566-83A priority patent/SK279249B6/sk
Priority to CS833566A priority patent/CZ280677B6/cs
Priority to IT21217/83A priority patent/IT1203702B/it
Priority to EP83902157A priority patent/EP0109441B1/en
Priority to JP58502264A priority patent/JPS60501359A/ja
Priority to ES522585A priority patent/ES522585A0/es
Priority to HU832697A priority patent/HU190908B/hu
Priority to PCT/US1983/000781 priority patent/WO1983004313A1/en
Priority to DE3382764T priority patent/DE3382764T2/de
Priority to PH28943A priority patent/PH23031A/en
Priority to AU17729/83A priority patent/AU560595B2/en
Priority to AT83902157T priority patent/ATE114189T1/de
Priority to KR1019830002232A priority patent/KR880001567B1/ko
Priority to IL68752A priority patent/IL68752A/xx
Priority to ZA833686A priority patent/ZA833686B/xx
Priority to IT8348350A priority patent/IT8348350A0/it
Priority to NZ204327A priority patent/NZ204327A/en
Priority to IN683/CAL/83A priority patent/IN157982B/en
Publication of JPS58201994A publication Critical patent/JPS58201994A/ja
Priority to ES528897A priority patent/ES8504463A1/es
Priority to FI840219A priority patent/FI86077C/fi
Priority to NO840215A priority patent/NO165510C/no
Priority to DK025084A priority patent/DK164510C/da
Priority to PH32453A priority patent/PH21344A/en
Priority to US07/113,212 priority patent/US5286647A/en
Publication of JPH0159878B2 publication Critical patent/JPH0159878B2/ja
Priority to JP5168343A priority patent/JPH07121221B2/ja
Priority to JP5168345A priority patent/JPH07119240B2/ja
Priority to US08/443,810 priority patent/US6051229A/en
Priority to US08/480,014 priority patent/US6051387A/en
Priority to US08/482,197 priority patent/US6051693A/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP57084843A 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法 Granted JPS58201994A (ja)

Priority Applications (31)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
CA000428517A CA1247538A (en) 1982-05-21 1983-05-19 Human-human hybridomas for solid tumors
SK3566-83A SK279249B6 (sk) 1982-05-21 1983-05-19 Ľudské monoklonálne protilátky a spôsob ich výroby
CS833566A CZ280677B6 (cs) 1982-05-21 1983-05-19 Lidské monoklonální protilátky a způsob jejich výroby
IT21217/83A IT1203702B (it) 1982-05-21 1983-05-20 Ibridomi uomo-uomo per carcinomi cervicali
EP83902157A EP0109441B1 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
JP58502264A JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ
ES522585A ES522585A0 (es) 1982-05-21 1983-05-20 Un metodo para determinar la presencia de una neoplasia.
HU832697A HU190908B (en) 1982-05-21 1983-05-20 Process for preparing humane-humane hybridomes and - by means thereof - monoclonal antibodies
PCT/US1983/000781 WO1983004313A1 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
DE3382764T DE3382764T2 (de) 1982-05-21 1983-05-20 Humane-humane hybridomas für neoplasmen.
PH28943A PH23031A (en) 1982-05-21 1983-05-20 Human-human hybridomas for cervical carcinoma
AU17729/83A AU560595B2 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
AT83902157T ATE114189T1 (de) 1982-05-21 1983-05-20 Humane-humane hybridomas für neoplasmen.
KR1019830002232A KR880001567B1 (ko) 1982-05-21 1983-05-21 경부암을 위한 인체-인체융합세포
IL68752A IL68752A (en) 1982-05-21 1983-05-22 Human hybridomas cell lines producing monoclonal antibodies capable of distinguishing neoplastic cells from normal cells,antibodies produced by them and method for determining the presence of a neoplasm by using said antibodies
NZ204327A NZ204327A (en) 1982-05-21 1983-05-23 Human monoclonal antibodies against human neoplastic cells;human hybridomas producing such antibodies;diagnostic procedures
ZA833686A ZA833686B (en) 1982-05-21 1983-05-23 Human human hybridomas for cervical carcinoma
IT8348350A IT8348350A0 (it) 1982-05-21 1983-05-23 Ibridoma uomo-uomo per carcinoma cervicale
IN683/CAL/83A IN157982B (https=) 1982-05-21 1983-05-31
ES528897A ES8504463A1 (es) 1982-05-21 1984-01-16 Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas
FI840219A FI86077C (fi) 1982-05-21 1984-01-19 Monoklonala antikroppar och metod att producera dessa.
NO840215A NO165510C (no) 1982-05-21 1984-01-20 Monoklonale antistoffer, samt anvendelse av dem in vitro for bestemmelse av naervaer av neoplasmer.
DK025084A DK164510C (da) 1982-05-21 1984-01-20 Humant hybridom, humant monoklonalt antistof opnaaet derfra, anvendelse af et saadant antistof og fremgangsmaade til fremstilling af et saadant antistof
PH32453A PH21344A (en) 1982-05-21 1985-06-25 Human-human hybridomas for cervical carcinoma
US07/113,212 US5286647A (en) 1982-05-21 1987-10-23 Human-human hybridomas for neoplasms
JP5168343A JPH07121221B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
JP5168345A JPH07119240B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン
US08/443,810 US6051229A (en) 1982-05-21 1995-05-18 Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
US08/480,014 US6051387A (en) 1982-05-21 1995-06-07 Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
US08/482,197 US6051693A (en) 1982-05-21 1995-06-07 CLNH11-specific antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP5168345A Division JPH07119240B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン
JP5168343A Division JPH07121221B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ

Publications (2)

Publication Number Publication Date
JPS58201994A true JPS58201994A (ja) 1983-11-25
JPH0159878B2 JPH0159878B2 (https=) 1989-12-20

Family

ID=13842073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP57084843A Granted JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
JP58502264A Pending JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP58502264A Pending JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ

Country Status (13)

Country Link
EP (1) EP0109441B1 (https=)
JP (2) JPS58201994A (https=)
AT (1) ATE114189T1 (https=)
AU (1) AU560595B2 (https=)
CZ (1) CZ280677B6 (https=)
DE (1) DE3382764T2 (https=)
DK (1) DK164510C (https=)
FI (1) FI86077C (https=)
HU (1) HU190908B (https=)
IN (1) IN157982B (https=)
SK (1) SK279249B6 (https=)
WO (1) WO1983004313A1 (https=)
ZA (1) ZA833686B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6012973A (ja) * 1983-03-11 1985-01-23 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 悪性黒色腫のある患者のリンパ球からのヒトの単一クロ−ン抗体
JPS6024184A (ja) * 1983-03-09 1985-02-06 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ ガン細胞に対するヒトのモノクロ−ン抗体の反応
JPS60260597A (ja) * 1984-01-31 1985-12-23 アクゾ　ナムローゼ　フェンノートシャップ 自己由来のワクチン
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
JPS61204134A (ja) * 1984-10-15 1986-09-10 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ−・オブ・カリフオルニア 癌細胞に対する抗体を産生するヒト−ヒトハイブリド−マ細胞系
JPS6299332A (ja) * 1985-10-26 1987-05-08 Hagiwara Yoshihide 悪性腫瘍用ヒトモノクロナル抗体複合剤
JPS62163686A (ja) * 1986-01-13 1987-07-20 Mitsubishi Chem Ind Ltd 抗体産生細胞株の樹立方法
WO1992020799A1 (fr) * 1991-05-22 1992-11-26 Hagiwara, Yoshihide Sequence d'acides amines d'anticorps monoclonal humain anticancer et sequence de bases d'adn codant pour ces acides amines

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
ES8802196A1 (es) * 1984-03-30 1988-04-16 Syntex Inc Metodo para determinar la presion de un estado maligno en tejidos.
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US5434076A (en) * 1989-12-18 1995-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
EP0528663B1 (en) * 1991-08-16 1997-10-29 Kabushiki Kaisha Toshiba Monoclonal antibody to a synaptophysin
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
AU784460B2 (en) 1999-08-23 2006-04-06 Chugai Seiyaku Kabushiki Kaisha HM1.24 antigen expression potentiators
DK1222854T3 (da) 1999-10-01 2011-03-14 Chugai Pharmaceutical Co Ltd Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE602004028249D1 (de) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd Fucosetransporter
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
WO2005054467A1 (ja) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 哺乳類βアクチンプロモーターを利用した発現系
WO2005056605A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
SI1674111T1 (sl) 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2011870A4 (en) 2006-04-14 2010-09-15 Medical & Biol Lab Co Ltd MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
DE602006013809D1 (de) 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
EP2050466B1 (en) 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
CN103396486A (zh) 2006-10-12 2013-11-20 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
EP2130552B1 (en) 2007-02-27 2016-06-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
EP2175016A4 (en) 2007-06-25 2012-03-28 Forerunner Pharma Res Co Ltd ANTI-PROMININ-1 ANTIBODY WITH ADCC ACTIVITY OR CDC ACTIVITY
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
CA2728243C (en) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
RU2011131071A (ru) 2008-12-26 2013-02-10 Дзе Юниверсити Оф Токио Диагностика и лечение рака с помощью антитела против lgr7
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011013786A1 (ja) 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
LT2535358T (lt) 2010-02-10 2018-03-26 Fujifilm Ri Pharma Co., Ltd. Radioaktyvus metalu žymėtas anti-kadherino antikūnas
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
CN103491978A (zh) 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
ES2931477T3 (es) 2010-10-29 2022-12-29 Perseus Proteomics Inc Anticuerpo anti-CDH3 que tiene alta capacidad de internalización
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
US9616101B2 (en) 2012-07-06 2017-04-11 Kyoto Prefectural Public University Corporation Differentiation marker and differentiation control of eye cell
TWI606066B (zh) 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
JP6514645B2 (ja) 2013-12-27 2019-05-15 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2018174274A1 (ja) 2017-03-24 2018-09-27 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
SG11202108494YA (en) 2019-02-28 2021-09-29 Juntendo Educational Found Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
US20220227887A1 (en) 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
JP7769386B2 (ja) 2020-04-06 2025-11-13 株式会社PhotoQ3 腫瘍細胞を死滅させるための医薬
CN116194473A (zh) 2020-07-28 2023-05-30 中外制药株式会社 包含新改造型抗体的具备针护罩的带针预充注射器制剂
CN116322763A (zh) 2020-08-27 2023-06-23 学校法人顺天堂 抗切断型突变calr-cd3双特异性抗体及医药组合物
IL305793A (en) 2021-03-12 2023-11-01 Hoffmann La Roche A pharmaceutical preparation for the treatment or prevention of myasthenia gravis
EP4412583A1 (en) 2021-10-04 2024-08-14 Novartis AG Surfactant stabilizers
AU2022399314A1 (en) 2021-12-01 2024-06-20 Chugai Seiyaku Kabushiki Kaisha Method for preparing antibody-containing formulation
TW202342097A (zh) 2022-02-25 2023-11-01 學校法人順天堂 抗突變calr抗體與其他藥劑組合而成之醫藥
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001461A1 (en) * 1980-07-18 1982-05-13 Leland Stanford Junior Univ Human hybridomas,precursors and products
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024184A (ja) * 1983-03-09 1985-02-06 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ ガン細胞に対するヒトのモノクロ−ン抗体の反応
JPS6012973A (ja) * 1983-03-11 1985-01-23 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 悪性黒色腫のある患者のリンパ球からのヒトの単一クロ−ン抗体
JPS60260597A (ja) * 1984-01-31 1985-12-23 アクゾ　ナムローゼ　フェンノートシャップ 自己由来のワクチン
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
JPS61204134A (ja) * 1984-10-15 1986-09-10 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ−・オブ・カリフオルニア 癌細胞に対する抗体を産生するヒト−ヒトハイブリド−マ細胞系
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
JPS6299332A (ja) * 1985-10-26 1987-05-08 Hagiwara Yoshihide 悪性腫瘍用ヒトモノクロナル抗体複合剤
JPS62163686A (ja) * 1986-01-13 1987-07-20 Mitsubishi Chem Ind Ltd 抗体産生細胞株の樹立方法
WO1992020799A1 (fr) * 1991-05-22 1992-11-26 Hagiwara, Yoshihide Sequence d'acides amines d'anticorps monoclonal humain anticancer et sequence de bases d'adn codant pour ces acides amines

Also Published As

Publication number Publication date
DK164510C (da) 1992-11-23
FI86077C (fi) 1992-07-10
AU1772983A (en) 1983-12-16
ATE114189T1 (de) 1994-12-15
EP0109441A4 (en) 1986-09-22
ZA833686B (en) 1984-09-26
EP0109441B1 (en) 1994-11-17
FI840219A0 (fi) 1984-01-19
FI86077B (fi) 1992-03-31
IN157982B (https=) 1986-08-09
JPH0159878B2 (https=) 1989-12-20
EP0109441A1 (en) 1984-05-30
WO1983004313A1 (en) 1983-12-08
HU190908B (en) 1986-12-28
DK25084A (da) 1984-01-20
JPS60501359A (ja) 1985-08-22
DK164510B (da) 1992-07-06
FI840219L (fi) 1984-01-19
DK25084D0 (da) 1984-01-20
SK356683A3 (en) 1998-08-05
CZ280677B6 (cs) 1996-04-17
DE3382764D1 (de) 1994-12-22
AU560595B2 (en) 1987-04-09
DE3382764T2 (de) 1995-03-16
SK279249B6 (sk) 1998-08-05
CZ356683A3 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
JPS58201994A (ja) 抗原特異的ヒト免疫グロブリンの生産方法
JP2648419B2 (ja) モノクローナル抗体混合物
US4634664A (en) Process for the production of human mono-clonal antibodies
CA1187010A (en) Cell-driven viral transfer in eukaryotes
KR930012104B1 (ko) 암-관련 항원-특이적 인간 면역 글로불린 및 인간 면역 글로불린을 생산하는 능력을 갖는 인간/인간 하이브리도마
JPS59137497A (ja) 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
US4752582A (en) Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
WO1983001739A1 (en) Monoclonal antibodies against brugia malayi
KR880001567B1 (ko) 경부암을 위한 인체-인체융합세포
US5330896A (en) Monoclonal antibodies to an autocrine growth factor antigen that binds to activated lymphocytes and cancer cells
EP0363703A1 (en) Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof
US5279958A (en) Surface protein of basal epidermal cells, antibodies capable of recognizing said protein, and their use, and hybrid cellular stocks capable of secreting such antibodies
Gaffar et al. Strategies for the design and use of tumor‐reactive human monoclonal antibodies
JPH06153932A (ja) 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
US5039793A (en) Cytoplasmic protein of suprabasal epidermal cells, antibodies capable of recognizing said protein, and hybrid cellular stocks capable of secreting such antibodies
JP2509191B2 (ja) ガン関連抗原特異的ヒト免疫グロブリン
JPH07119240B2 (ja) 抗原特異的ヒト免疫グロブリン
Tilz et al. Antigenic Determinants of Migratory Cells
JPS59135898A (ja) 抗原特異的ヒト免疫グロブリンの生産方法
JP2599258B2 (ja) ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
JPH05268988A (ja) ガン関連抗原特異的ヒト免疫グロブリン
JPH05207876A (ja) ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
Brown The Production of Monoclonal Antibodies by Cell Fusion
JPH01500722A (ja) 膵臓α‐アミラーゼに対する抗体の産生及び診断への使用
JPS6356299A (ja) 腫よう関連抗原